UnicoCell Biomed Co., Ltd. Statistics
UnicoCell Biomed Co., Ltd. (6794) Stock Statistics & Valuation Metrics
Total Valuation
UnicoCell Biomed Co., Ltd. has a market cap or net worth of TWD 4.10B. The enterprise value is TWD 4.41B.
- Market Cap
- TWD 4.10B
- Enterprise Value
- TWD 4.41B
Share Statistics
UnicoCell Biomed Co., Ltd. has 63,637,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 63,637,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
UnicoCell Biomed Co., Ltd.’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.98%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -13.98%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 1.11M
- Profits Per Employee
- -4.25M
- Employee Count
- 27
- Asset Turnover
- 0.03
- Inventory Turnover
- 3.27
Valuation Ratios
The current PE Ratio of UnicoCell Biomed Co., Ltd. is -34.39. UnicoCell Biomed Co., Ltd.’s PEG ratio is 1.61.
- PE Ratio
- -34.39
- PS Ratio
- 137.41
- PB Ratio
- 4.84
- Price to FCF
- -100.47
- Price to Operating Cash Flow
- -98.37
- PEG Ratio
- 1.61
Income Statement
In the last 12 months, UnicoCell Biomed Co., Ltd. had revenue of 30.10M and earned -114.84M in profits. Earnings per share was -1.89.
- Revenue
- 30.10M
- Gross Profit
- -221.00K
- Operating Income
- -130.28M
- Pretax Income
- -114.84M
- Net Income
- -114.84M
- EBITDA
- -109.73M
- Earnings Per Share (EPS)
- -1.89
Cash Flow
In the last 12 months, operating cash flow was -74.18M and capital expenditures -1.79M, giving a free cash flow of -75.97M billion.
- Operating Cash Flow
- -74.18M
- Free Cash Flow
- -75.97M
- Free Cash Flow per Share
- -0.68
Dividends & Yields
UnicoCell Biomed Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.00%
- Earnings Yield
- -2.90%
Stock Price Statistics
- Beta
- 0.23
- 52-Week Price Change
- -5.43%
- 50-Day Moving Average
- 72.10
- 200-Day Moving Average
- 78.52
- Relative Strength Index (RSI)
- 27.00
- Average Volume (3m)
- 42.84K
Important Dates
UnicoCell Biomed Co., Ltd. upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
UnicoCell Biomed Co., Ltd. as a current ratio of 37.98, with Debt / Equity ratio of 7.17%
- Current Ratio
- 37.98
- Quick Ratio
- 37.53
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.19
- Interest Coverage Ratio
- -97.29
Taxes
In the past 12 months, UnicoCell Biomed Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
UnicoCell Biomed Co., Ltd. EV to EBITDA ratio is -37.81, with an EV/FCF ratio of -100.77.
- EV to Sales
- 137.82
- EV to EBITDA
- -37.81
- EV to Free Cash Flow
- -100.77
- EV to Operating Cash Flow
- -103.10
Balance Sheet
UnicoCell Biomed Co., Ltd. has TWD 752.02M in cash and marketable securities with TWD 62.02M in debt, giving a net cash position of TWD 690.00M billion.
- Cash & Marketable Securities
- TWD 752.02M
- Total Debt
- TWD 62.02M
- Net Cash
- TWD 690.00M
- Net Cash Per Share
- TWD 10.84
- Tangible Book Value Per Share
- TWD 14.21
Margins
Gross margin is -0.73%, with operating margin of -432.77%, and net profit margin of -381.48%.
- Gross Margin
- -0.73%
- Operating Margin
- -432.77%
- Pretax Margin
- -381.48%
- Net Profit Margin
- -381.48%
- EBITDA Margin
- -364.51%
- EBIT Margin
- -432.77%
Analyst Forecast
The average price target for UnicoCell Biomed Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -48.98%
- EPS Growth Forecast
- -2.09%
